| Yazarlar (1) |
Doç. Dr. Selin ÖZKAN KOTİLOĞLU
Kırşehir Ahi Evran Üniversitesi, Türkiye |
| Özet |
| Background & Aims The anxiolytic benzodiazepine diazepam (DZP) was first introduced and licensed in the United States in 1963. It is categorized as a benzodiazepine with both long-acting and fast-acting properties. It is frequently recommended to treat a range of diseases including acute recurring seizures, severe muscle spasms, stiffness related to neurological illnesses, anxiety disorders, and alcohol withdrawal. DZP is highly efficient in relieving symptoms associated with acute alcohol withdrawal, such as restlessness, shaking, drunk hallucinations, and severe delirium tremens. The therapeutic drug monitoring (TDM) of DZP is crucial for observing patients’ adherence to treatment. Furthermore, the detection of diazepam and its major metabolite (NDZP) holds significant importance in forensic toxicology due to its potential for misuse. There are several reasons why NDZP was chosen for this study. These; It is a … |
| Anahtar Kelimeler |
| Bildiri Türü | Tebliğ/Bildiri |
| Bildiri Alt Türü | Poster Olarak Sergilenen Tebliğ (Uluslararası Kongre/Sempozyum) |
| Bildiri Niteliği | Web of Science Kapsamındaki Kongre/Sempozyum |
| Bildiri Dili | İngilizce |
| Kongre Adı | TIAFT 2024 |
| Kongre Tarihi | 02-09-2024 / 06-09-2024 |
| Basıldığı Ülke | İsviçre |
| Basıldığı Şehir |
